Target market determination (TMD)
Released
Released
Announcement PDF
TARGET MARKET
TARGET MARKET DETERMINATION
MADE BY: Radiopharm Theranostics Limited ACN 647 877 889 of Suite 1, Level 3, 62 Lygon Street,
Carlton South, VIC 3053 (Company)
PRODUCT: Free attaching options (Attaching Options) in connection with an offer of shares in
the Company (Shares) by Share Purchase Plan (SPP) under a prospectus dated
20 October 2025 (Prospectus).
EFFECTIVE DATE: 20 October 2025
This target market determination (TMD) has been prepared by the Company in relation to an offer to issue the
Attaching Options made by the Company under the Prospectus (Offer). A copy of the Prospectus is available
on the Company’s website, www.radiopharmtheranostics.com.
Bell Potter Securities Limited has been appointed as lead manager (Lead Manager) to the Offer.
The Offer is made under the Prospectus. Any recipient of this TMD should carefully read and consider the
Prospectus in full and consult their professional adviser if they have any questions regarding the contents of
the Prospectus. Any recipient of this TMD who wants to acquire Attaching Options under the Offer will need to
follow the instructions in the application form that will accompany the Prospectus. There is no cooling off period
in respect of the issue of the Attaching Options.
This TMD is not a disclosure document for the purposes of the Corporations Act 2001 (Cth), and therefore has
not been lodged, and does not require lodgement, with the Australian Securities and Investments Commission
(ASIC).
This TMD does not take into account what you currently have, or what you want and need, for your financial
future. It is important for you to consider these matters and read the Prospectus before you make an investment
decision. The Company is not licensed to provide financial product advice in relation to the Attaching Options.
TARGET MARKET DETERMINATION (TMD)
The product (Attaching Options) is likely to be appropriate for a consumer seeking exposure to the
radiopharmaceutical sector and:
1. should the Company’s radiopharmaceutical developments be successful, exposure to potential for capital
growth; and
2. for inclusion as part of a diversified portfolio where the consumer has a medium to long term investment
timeframe (if the product is exercised and the resultant Shares are issued).
Class of
consumers that
fall within this
target market
The Attaching Options have been designed for investors whose likely
objectives, financial situation and needs are aligned with the product
(including the key attributes).
The Attaching Options are for those who:
are permitted to acquire securities pursuant to the Prospectus and
subscribe for Shares to which the Attaching Options attach under the
Prospectus;
seek to profit from an appreciation in the market price of Shares in the
Company and/or who have a long-term view on the Shares or the
underlying assets of the Company;
wish to participate in any potential future distribution should operations be
successful; and
TARGET MARKET DETERMINATION
are accustomed to participating in speculative investments in the
radiopharmaceutical sector.
The Attaching Options are issued only to applicants under the Offer and
consequently have been designed for consumers who:
will acquire Shares and Attaching Options under the Offer;
have the financial ability to consider the economic risk of the exercise of
the Attaching Options;
given the speculative nature of the Shares and Attaching Options, have
adequate means to provide for their current needs and to withstand a loss
of the entire investment of the Shares and Attaching Options;
have such knowledge and experience in financial and business matters
that they are capable of evaluating the merits and risks of exercising the
Attaching Options; and
have determined that the Shares and Attaching Options are a suitable
investment.
The key product attributes of the Attaching Options are described in the
Prospectus and in summary are:
the holders of Attaching Options will be entitled to one Share upon
exercise of each one Option;
the Attaching Options will be issued for nil consideration and are
exercisable at $0.039 per Attaching Option with an expiry date of 31
October 2027;
the Company intends that the Attaching Options will be quoted on the
ASX; and
approximately 166,666,667 Attaching Options are expected be issued
under the Offer.
Excluded class of
consumers
The Attaching Options have not been designed for retail individuals who:
require an income stream from their investment;
do not ordinarily invest in speculative investments in the
radiopharmaceutical sector;
are resident outside of Australia or New Zealand; and/or
are not applicants under the Offer.
Conditions and
restrictions on
distribution
The key restrictions on distribution of the Attaching Options are the Offer,
which includes the Attaching Options, is only being made to shareholders
in the Company at the record date of 17 October 2025 and with a
registered address in Australia or New Zealand, or otherwise to the extent
permitted under the Prospectus (Eligible Shareholders).
The Company considers that these distribution conditions will ensure that
persons who invest in the Attaching Options fall within the target market
(those who have received and apply under the Prospectus and subscribe
for Shares to which the Attaching Options attach).
Review Triggers As the Offer of the Attaching Options is to a discrete class of persons (being
the Eligible Shareholders), is only open for a limited time under the
Prospectus, and the Company is subject to continuous disclosure
requirements, the Company considers it is not necessary or appropriate to
implement the requirement of periodic reviews of this TMD.
TARGET MARKET DETERMINATION
The Company will review this TMD where any event or circumstance has
arisen that would suggest this TMD is no longer appropriate. This may
include (but is not limited to):
ASIC raises concerns with the Company regarding the adequacy of the
design or distribution of the Attaching Options or this TMD;
the occurrence of a significant dealing (as that term is described in ASIC
Regulatory Guide 274.158);
an unreasonable number of consumer complaints or feedback from those
who distribute or acquire the product; and
significant adverse changes to the Company's circumstances.
This TMD will be reviewed within 10 business days upon the occurrence of a
review trigger.
Maximum Period Subject to any review triggers, the maximum period of this TMD is from 20
October 2025 to 20 December 2025.
Reporting
Requirements
Complaints relating to the Attaching Options should be provided directly to
the Company as soon as practicable by any person including distributors of
the Attaching Options. The Company will review all complaints received in
relation to the Attaching Options on a continuous basis.
Distributors (such as the Lead Manager) who become aware of any
significant dealings (as that term is described in ASIC Regulatory Guide
274.158) must notify the Company as soon as practicable but no later than
10 business days after the distributor becomes aware of the significant
dealing.
Distributors (such as the Lead Manager) who become aware of any dealings
outside of the target market or receive complaints that would reasonably
suggest that the TMD is no longer appropriate must notify the Company as
soon as practicable but no later than 10 business days after the distributor
becomes aware of the dealing or complaint outside of the target market with
such information as reasonably necessary to allow the Company to identify
the kinds of persons dealing or giving such complaints.
The Company will not be in a position to determine any dealings that occur
upon exercise of the Attaching Option or on-sale of any resultant Share, as it
has no capacity to identify the objectives, financial situation and needs of
investors who exercise the Attaching Options or acquire the resultant Shares.
Share your feedback
Discover